Connection

Jacobo Mintzer to Double-Blind Method

This is a "connection" page, showing publications Jacobo Mintzer has written about Double-Blind Method.
Connection Strength

0.915
  1. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr. 2014 Feb; 26(2):239-46.
    View in: PubMed
    Score: 0.086
  2. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov; 15(11):918-31.
    View in: PubMed
    Score: 0.056
  3. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91.
    View in: PubMed
    Score: 0.050
  4. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry. 2003 Apr; 18(4):292-7.
    View in: PubMed
    Score: 0.041
  5. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry. 2001 Dec; 16 Suppl 1:S71-7.
    View in: PubMed
    Score: 0.037
  6. Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial. J Neurotrauma. 2021 07 15; 38(14):1943-1952.
    View in: PubMed
    Score: 0.036
  7. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019 11; 15(11):1427-1436.
    View in: PubMed
    Score: 0.032
  8. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72.
    View in: PubMed
    Score: 0.025
  9. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. J Psychiatr Res. 2016 Mar; 74:17-21.
    View in: PubMed
    Score: 0.025
  10. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91.
    View in: PubMed
    Score: 0.024
  11. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015 Sep 22-29; 314(12):1242-54.
    View in: PubMed
    Score: 0.024
  12. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015 Dec; 27(12):2059-67.
    View in: PubMed
    Score: 0.024
  13. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64.
    View in: PubMed
    Score: 0.024
  14. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33.
    View in: PubMed
    Score: 0.024
  15. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014; 9(6):e98426.
    View in: PubMed
    Score: 0.022
  16. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19; 311(7):682-91.
    View in: PubMed
    Score: 0.022
  17. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24.
    View in: PubMed
    Score: 0.022
  18. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 01; 311(1):33-44.
    View in: PubMed
    Score: 0.022
  19. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013 Aug; 74(8):810-6.
    View in: PubMed
    Score: 0.021
  20. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimers Dement. 2014 Jan; 10(1):36-44.
    View in: PubMed
    Score: 0.021
  21. Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). Am J Geriatr Psychiatry. 2013 Jun; 21(6):549-59.
    View in: PubMed
    Score: 0.020
  22. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44.
    View in: PubMed
    Score: 0.020
  23. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012 Oct 18; 367(16):1497-507.
    View in: PubMed
    Score: 0.020
  24. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2012 Sep; 27(6):421-32.
    View in: PubMed
    Score: 0.020
  25. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012 Apr; 20(4):362-73.
    View in: PubMed
    Score: 0.019
  26. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012; 8(2):121-30.
    View in: PubMed
    Score: 0.019
  27. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45.
    View in: PubMed
    Score: 0.017
  28. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008 Feb; 5(1):83-9.
    View in: PubMed
    Score: 0.014
  29. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May; 22(5):475-84.
    View in: PubMed
    Score: 0.014
  30. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007 Feb; 4(1):81-93.
    View in: PubMed
    Score: 0.013
  31. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.
    View in: PubMed
    Score: 0.013
  32. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005 Nov; 13(11):942-9.
    View in: PubMed
    Score: 0.012
  33. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004 Jan; 19(1):9-18.
    View in: PubMed
    Score: 0.011
  34. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003 Nov; 160(11):2003-11.
    View in: PubMed
    Score: 0.011
  35. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
    View in: PubMed
    Score: 0.011
  36. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002 Apr; 26(4):494-504.
    View in: PubMed
    Score: 0.010
  37. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001 Nov; 71(5):589-95.
    View in: PubMed
    Score: 0.009
  38. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase. 2001; 7(2):105-10.
    View in: PubMed
    Score: 0.009
  39. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12; 52(6):1146-52.
    View in: PubMed
    Score: 0.008
  40. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb; 60(2):107-15.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.